The purpose of the study is to determine the plasma levels of CRD007 in patients with abdominal aortic aneurysms after the administration of single doses of tablets containing 10, 25 and 40 mg CRD007.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
18
Department of Vascular Surgery Viborg Hospital
Viborg, Denmark, Denmark
Pharmacokinetics - maximum plasma concentration (Cmax)
Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as Cmax will be measured
Time frame: Pre-dose and until 12 hours post-dose
Pharmacokinetics - time to maximum plasma concentration (tmax)
Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as tmax will be measured.
Time frame: Pre-dose til 12 hours post-dose
Pharmacokinetics - Area under the plasma concentration curve (AUC)
Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as AUC will be measured.
Time frame: Pre-dose until 12 hours post-dose
Pharmacokinetics - elimination half life (t1/2)
Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as t1/2 will be measured
Time frame: pre-dose until 12 hours post-dose
Dose linearity
Evaluation of dose linearity in the dose range 10 - 40 mg
Time frame: Pre-dose and until 12 hours post-dose
Potential for accumulation
To estimate the accumulation of CRD007 in the dose range 10 - 40 mg
Time frame: Pre-dose untill 12 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.